Samsung Biologics Wins Backing For $1.8B PolyPeptide Buy
Samsung Biologics said Monday it has provisionally secured nearly all the backing of shareholders of PolyPeptide Group in a public tender offer to acquire the drug manufacturer for an estimated 1.46...To view the full article, register now.
Already a subscriber? Click here to view full article